Atreca, Inc.

Bayer Healthcare LLC

Immunome, Inc.

Shaun M Lippow

Wayne Volkmuth

Daniel Eric Emerling

Tito Serafini

Jeff DeFalco

Randal Robert Ketchem

William H Robinson

Richard L Feldman

Alan Richard Brooks

Yann Chong Tan

Peter Bringmann

Sean W Carroll

Sean Matthew Carroll

Philippe Marguet

Amy Manning-Bog

Ngan Nguyen Atkins

Jian-Ming Gu

Alexander Scholz

Nikhil Vad

Katherine L Williams

Norm Greenberg

Jessica Finn

Michael Samuel Weiss

Shuning Gai

Fengling Liu

Anne Ye

Norman Michael Greenberg

Danhui Zhang

Shujun Yuan

Iraz T Aydin

Vera Huang

Maryam M Bhatti

Jeff Defalco

Provided herein are EphA2 antibodies. These EphA2 antibodies bind preferentially to tumor tissue than normal tissue and bind to EphA2. Such antibodies are used in methods of inducing an immune response and methods of inhibiting tumor cell growth. Additionally provided are methods of producing such antibodies.

EPHA2 antibodies

The present disclosure provides anti-circumsporozoite (CSP) antibodies, compositions comprising such antibodies. Also disclosed are methods of producing the disclosed antibodies and methods of treating or preventing malaria using the same.

Anti-CSP antibodies

Provided herein are antibodies that bind to tumor tissue through a binding interaction with an extracellular RNA-protein complex. Such antibodies are used in methods of inducing an immune response and methods of inhibiting tumor cell growth. Additionally provided are methods of producing such antibodies.

Antibodies that bind tumor tissue for diagnosis and therapy

Targeted Factor VIII molecules comprising a Factor VIII linked with at least one domain that specifically binds to a membrane protein on a red blood cell is provided. The disclosed targeted coagulation factors prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.

Red blood cell targeted factor VIII and method of using the same

Disclosed herein are methods and compositions for using nanoexpression to interrogate antigen specificity within antibody repertoires. Also disclosed herein is an antibody display system composition comprising one or more recombinant nucleic acid sequences comprising a first nucleic acid sequence encoding a heavy chain variable region sequence or fragment thereof operatively linked to a first identification region sequence and a second nucleic acid sequence encoding a light chain variable region sequence or fragment thereof operatively linked to a second identification region sequence.

Use of nanoexpression to interrogate antibody repertoires

Growing community of inventors

San Carlos, CA, United States of America

Shaun M Lippow